Vascular contributions to cognitive impairment are increasingly recognized 1-5 as shown by neuropathological 6,7 , neuroimaging 4,8-11 , and cerebrospinal fluid biomarker 4,12 studies. Moreover, small vessel disease of the brain has been estimated to contribute to approximately 50% of all dementias worldwide, including those caused by Alzheimer's disease (AD) 3, 4, 13 . Vascular changes in AD have been typically attributed to the vasoactive and/or vasculotoxic effects of amyloid-β (Aβ) 3, 11, 14 , and more recently tau 15 . Animal studies suggest that Aβ and tau lead to blood vessel abnormalities and blood-brain barrier (BBB) breakdown [14] [15] [16] . Although neurovascular dysfunction 3, 11 and BBB breakdown develop early in AD 1,4,5,8-10,12,13 , how they relate to changes in the AD classical biomarkers Aβ and tau, which also develop before dementia 17 , remains unknown. To address this question, we studied brain capillary damage using a novel cerebrospinal fluid biomarker of BBB-associated capillary mural cell pericyte, soluble platelet-derived growth factor receptor-β 8,18 , and regional BBB permeability using dynamic contrast-enhanced magnetic resonance imaging [8] [9] [10] . Our data show that individuals with early cognitive dysfunction develop brain capillary damage and BBB breakdown in the hippocampus irrespective of Alzheimer's Aβ and/or tau biomarker changes, suggesting that BBB breakdown is an early biomarker of human cognitive dysfunction independent of Aβ and tau.
We studied individuals who were cognitively normal as well as individuals with early cognitive dysfunction who were stratified on cerebrospinal fluid (CSF) analysis as either amyloid-β (Aβ )-positive (Aβ 42 + , < 190 pg ml −1 ) or Aβ -negative (Aβ 42 − , > 190 pg ml −1 ), or pTau-positive (pTau+ , > 78 pg ml −1 ) or pTau-negative (pTau− , < 78 pg ml −1 ), using accepted cutoff values [19] [20] [21] . Supplementary Tables  1 and 2 show the patient demographics, clinical data and prevalence of vascular risk factors (VRFs) by level of clinical dementia rating (CDR) score and the number of impaired cognitive domains, respectively. Individuals diagnosed with vascular dementia and vascular cognitive impairment, and other disorders that might account for cognitive impairment, were excluded (see Methods).
Platelet-derived growth factor receptor-β (PDGFRβ ) is primarily expressed in the brain by vascular mural cells-capillary pericytes and vascular smooth muscle cells (SMCs)-but not by neurons, astrocytes, endothelial cells, oligodendrocytes and/or microglia [22] [23] [24] [25] . PDGFRβ expression in pericytes is noticeably higher than in SMCs 18, 25, 26 . Human brain pericytes, but not SMCs, shed soluble PDGFRβ (sPDGFRβ ) in the culture media, which is increased by hypoxia or injurious stimuli 8, 18 . Additionally, loss of pericytes in mice elevates CSF sPDGFRβ 8 . In individuals with mild cognitive impairment, increased CSF sPDGFRβ correlates with increased dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) measures of blood-brain barrier (BBB) dysfunction 8 . Consistent with findings that a disintegrin and metalloproteinase 10 (ADAM10) sheds sPDGFRβ in fibroblasts 27 , we found that ADAM10 mediates sPDGFRβ shedding in human pericytes but not SMCs (Extended Data Fig. 1 ), supporting the hypothesis that sPDGFRβ is primarily a biomarker of brain capillary pericytes 8, 18 .
We found increased CSF sPDGFRβ with more advanced CDR impairment (CDR 1 > 0.5 > 0) ( Fig. 1a ), suggesting progressive damage of pericytes 8, 18 with cognitive dysfunction. There were no significant differences in CSF Aβ 42 or pTau levels between CDR 0.5 and CDR 0 individuals, although we saw reduced CSF Aβ 42 in CDR 1 relative to CDR 0.5 participants ( Fig. 1b,c ; for site-specific analysis, see Extended Data Fig. 2a,b) . sPDGFRβ was increased in participants with CDR 0.5 relative to CDR 0 regardless of CSF Aβ 42 (Fig. 1d ) or pTau ( Fig. 1e ) status, that is, irrespective of Aβ + or Aβ − , or pTau+ or pTau− , as confirmed by site-specific analyses (Extended Data Fig. 2c,d ). Higher CSF sPDGFRβ remained a significant predictor of cognitive impairment after statistically controlling for CSF Aβ 42 and pTau, as shown by the estimated marginal means from the analysis of covariance (ANCOVA) models ( Fig. 1f ), indicating medium-to-large incremental effect sizes with η 2 partial range = 0.10-0.12, which has been confirmed by logistic regression
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Letters NATurE MEDiciNE models ( Supplementary Table 3a -c). There was a significant positive correlation between CSF sPDGFRβ with classical biomarkers of BBB breakdown, including the CSF/plasma albumin ratio and CSF fibrinogen (Extended Data Fig. 2e,f) . Among the subset of 35 participants who underwent Pittsburgh compound B (PiB)positron emission tomography (PET), those with CDR 0.5 exhibited increased CSF sPDGFRβ relative to those with CDR 0, after statistically controlling for amyloid levels (Extended Data Fig. 2g ), consistent with CSF Aβ 42 findings (Fig. 1d ). Additionally, we found no differences in CSF Aβ and tau oligomer levels between the CDR 0 and CDR 0.5 groups (Extended Data Fig. 2h ,i). CSF sPDGFRβ remained significantly elevated in CDR analysis after statistically controlling for CSF tau oligomers in ANCOVA models (Extended Data Fig. 2j ), suggesting that sPDGFRβ increase is not dependent on oligomer levels.
Increased CSF sPDGFRβ in impaired individuals was independent of vascular factors, as indicated by the VRF burden analysis for the entire sample and confirmed by site-specific analysis (Extended Data Fig. 3a-c) . Of note, there were no differences in CSF biomarkers of glial and inflammatory response, or neuronal degeneration 28, 29 , between impaired and unimpaired individuals on CDR exams, as illustrated with a few representative biomarkers out of the 20 studied (see online Methods; Extended Data Fig. 4a ) and confirmed by site-specific analysis (Extended Data Fig. 4b,c ). Collectively, our findings indicate that damage to brain capillary pericytes, which critically maintain the BBB integrity 22, 30, 31 , develops early in older adults with cognitive dysfunction, is independent of Aβ and tau biomarker changes, is not influenced by VRFs, and is not associated with the glial and/or inflammatory response, or detectable neuronal degeneration.
The DCE-MRI analysis of regional BBB permeability in a subset of 73 participants with CDR 0.5 compared to those with CDR 0, indicated increased BBB permeability to gadolinium-based contrast agent in the hippocampus (HC) and its CA1, CA3, and dentate gyrus subfields, and parahippocampal gyrus (PHG), but not in other studied brain regions including the frontal and temporal cortex, subcortical white matter, corpus callosum, and internal capsule, and deep gray matter regions including the thalamus and striatum (Extended Data Fig. 5a,b ). These findings are consistent with a recent report demonstrating that BBB breakdown during normal aging and mild cognitive impairment starts in the HC 8 . Surprisingly, we also found that individuals with a CDR 0.5 compared to those who were cognitively normal (CDR 0) exhibited BBB breakdown in the HC, PHG, and HC subfields, regardless of CSF Aβ 42 (Fig. 1g ,h) and pTau ( Fig. 1i ,j) status. Increased regional BBB permeability in the HC, PHG, and HC subfields remained a significant predictor of cognitive impairment after statistically controlling for CSF Aβ 42 and pTau, as shown by the estimated marginal means from ANCOVA models ( Fig. 1k ) indicating medium-to-large incremental effect sizes (η 2 partial range = 0.09-0.28), also confirmed by logistic regression models ( Supplementary Table 3d , and pTau (c) levels in individuals with a CDR score of 0 (n = 82), 0.5 (n = 65), and 1 (n = 17). d, CSF sPDGFRβ in individuals with no cognitive impairment (CDR 0) who are CSF Aβ 42 negative (Aβ − ; n = 53) or positive (Aβ + ; n = 29), and with cognitive dysfunction (CDR 0.5) who are Aβ − (n = 38) or Aβ + (n = 38). e, CSF sPDGFRβ in CDR 0 participants who are CSF pTau-negative (pTau− ; n = 60) or positive (pTau+ ; n = 21) and CDR 0.5 participants who are pTau− (n = 33) or pTau+ (n = 29). f, CSF sPDGFRβ controlled for CSF Aβ 42 and pTau levels in CDR 0 (n = 80) and CDR 0.5 (n = 61) participants. Estimated marginal means ± s.e.m. from ANCOVA models. g,h, Representative BBB K trans maps in the HC and PHG (g), and quantification of K trans values in the HC, PHG, and the CA1, CA3, and dentate gyrus HC subfields in CDR 0 individuals who are Aβ − (n = 24) or Aβ + (n = 20) and CDR 0.5 participants who are Aβ − (n = 11) or Aβ + (n = 12) (h). i,j, Representative BBB K trans maps in the HC and PHG (i), and quantification of K trans values in the HC, PHG, and the CA1, CA3 and dentate gyrus HC subfields in individuals with CDR 0 who are pTau− (n = 32) or pTau+ (n = 12), and with CDR 0.5 who are pTau− (n = 14) or pTau+ (n = 8) (j). k, Regional K trans values controlled for CSF Aβ and pTau levels in CDR 0 (n = 44) and CDR 0.5 (n = 23) individuals. Estimated marginal means ± s.e.m. from ANCOVA models. The box and whisker plot lines indicate the median values, the boxes indicate the interquartile range (IQR) and the whiskers indicate the minimum and maximum values. Significance tests after FDR correction from ANCOVAs with post-hoc Bonferroni comparisons.
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Regional BBB analysis indicated that Aβ and tau status does not affect BBB integrity in other studied brain regions (Extended Data Fig. 5c,d ). Similar to the sPDGFRβ findings, VRF burden did not influence BBB permeability changes in the HC and PHG in individuals with CDR 0.5 compared to CDR 0, and had no effect on BBB integrity in other studied brain regions (Extended Data Fig. 5e ,f). Consistent with previous findings 8 , in the present cohort we also observed a significant positive correlation between increases in CSF sPDGFRβ and DCE-MRI measures of BBB permeability in the HC and PHG in all studied participants (Extended Data Fig. 5g ,h), which was not the case for other studied brain regions, as illustrated in this study for the white matter regions (Extended Data Fig. 5i,j ).
Because the present study sample excluded participants with vascular dementia and vascular cognitive impairment and substantial cerebrovascular pathology, it is probably not surprising that BBB dysfunction in the present analysis was independent of traditional systemic VRFs. However, the possibility of interactive or synergistic effects of traditional VRFs and BBB dysfunction in populations with more severe vascular lesions, vascular dementia, and vascular cognitive impairment is not ruled out by the present findings. Nevertheless, the fact that brain capillary mural cell damage and BBB breakdown is independent of traditional VRFs, as we show, is critical information that underscores the heterogeneity of vascular pathologies in the aging brain.
To address whether changes in CSF sPDGFRβ and DCE-MRI BBB permeability measures depend on HC volume, we conducted ANCOVA analyses and hierarchical logistic regression correcting for FreeSurfer-derived HC and/or PHG volumes ( Fig. 2a ). In participants with CDR 0.5 versus CDR 0, we found no significant changes in HC volume, but a significant decrease in PHG volume ( Fig. 2b ). HC or PHG volumes did not statistically differ between participants that were CSF Aβ + versus Aβ − ( Fig. 2c ) or pTau+ versus pTau− ( Fig. 2d ) in either the CDR 0 or CDR 0.5 groups. Importantly, CSF sPDGFRβ increases remained significant after controlling for HC and PHG volumes (estimated as marginal means from ANCOVA models) ( Fig. 2e) , and remained increased when stratifying by CSF Aβ 42 and pTau status ( Fig. 2f,g) . Similarly, the HC and PHG BBB permeability increases remained significant after controlling for HC and PHG volumes, respectively (Fig. 2h ), and when stratifying by Aβ 42 and pTau status ( Fig. 2i ,j). All findings exhibited mediumto-large incremental effect sizes after controlling for HC and PHG volume (η 2 partial range = 0.09-0.31) and were corroborated by logistic regression models ( Supplementary Table 4a 
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these data suggest that BBB impairment that is represented by CSF sPDGFRβ and DCE-MRI measures is not only independent of CSF AD biomarkers, but is also not correlated to HC volume.
To determine whether our findings hold when cognitive dysfunction was evaluated by neuropsychological performance, we analyzed CSF biomarkers and BBB integrity using normalized scores from and with one or more impaired cognitive domains that are Aβ − (n = 37) or Aβ + (n = 47). e, CSF sPDGFRβ in individuals with no impaired cognitive domains who are CSF pTau− (n = 63) or pTau+ (n = 19) and with one or more impaired cognitive domains who are pTau− (n = 39) or pTau+ (n = 38). f, CSF sPDGFRβ controlled for CSF Aβ 42 and pTau levels in individuals with 0 (n = 80) and 1+ impaired domains (n = 74). Estimated marginal means ± s.e.m. from ANCOVA models. g,h, Representative BBB K trans maps in the HC and PHG (g); quantification of K trans values in the HC, PHG, and the CA1, CA3, and dentate gyrus HC subfields in individuals with no impaired cognitive domains that are Aβ − (n = 25) or Aβ + (n = 20) and with one or more impaired cognitive domains who are Aβ − (n = 12) or Aβ + (n = 13) (h). i,j, Representative BBB K trans maps in the HC and PHG (j); quantification of K trans values in the HC, PHG, and the CA1, CA3, and dentate gyrus HC subfields in individuals with no impaired cognitive domains who are pTau− (n = 33) or pTau+ (n = 12) and with one or more impaired cognitive domains who are pTau− (n = 15) or pTau+ (n = 9) (j). k, Regional K trans values controlled for CSF Aβ and pTau levels in individuals with 0 (n = 45) and 1+ impaired domains (n = 22). Estimated marginal means ± s.e.m. from ANCOVA. The box and whisker plot lines indicate the median values, the boxes indicate the IQR, and the whiskers indicate the minimum and maximum values. Significance tests after FDR correction from ANCOVAs with post-hoc Bonferroni comparisons.
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ten neuropsychological tests used to evaluate impairment in memory, attention/executive function and language, and global cognition, as described in the online Methods. This analysis indicated elevated CSF sPDGFRβ in participants with one impaired cognitive domain relative to those with no impaired domains ( Fig. 3a ; see Extended Data Fig. 6a ,b for site-specific analyses). However, there was no difference in CSF Aβ 42 between participants with one impaired domain and those with no impaired domains ( Fig. 3b ), although participants with one impaired domain showed increased CSF pTau relative to those with no impaired domains ( Fig. 3c ).
Stratification of participants into those with and without classic AD biomarker abnormalities revealed increased CSF sPDGFRβ in participants with one or more impaired domains regardless of CSF Aβ 42 Higher CSF sPDGFRβ levels remained a significant predictor of cognitive impairment after statistically controlling for CSF Aβ 42 and pTau, as shown by the estimated marginal means from the ANCOVA models ( Fig. 3f ) indicating medium-to-large incremental effect sizes (η 2 partial range = 0.07− 0.14), which has been confirmed by logistic regression models at both sites ( Supplementary Table 5a -c).
Similar to the CDR analysis, in the subset of participants who underwent PiB-PET scans, participants with domain impairment exhibited increased CSF sPDGFRβ relative to those without impairment, after statistically controlling for amyloid levels (Extended Data Fig. 7a ), thus corroborating the CSF Aβ 42 data ( Fig. 3d ). There was no difference in CSF Aβ and tau oligomers between participants with impairment in one or more cognitive domains and those without cognitive impairment (Extended Data Fig. 7b ,c). CSF sPDGFRβ remained significantly increased in domain analysis after statistically controlling for CSF tau oligomers in the ANCOVA models (Extended Data Fig. 7d ).
There were no differences in CSF markers of glial and/or inflammatory response, or neuronal degeneration 28, 29 , between impaired and unimpaired participants on neuropsychological exams, as illustrated by a few examples (Extended Data Fig. 8a ; also confirmed by site-specific analysis in Extended Data Fig. 8b,c 
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Among participants undergoing DCE-MRI scans, those with domain impairment relative to those without impairment exhibited BBB breakdown in the HC, PHG, and HC subfields, but not in other studied brain regions (Extended Data Fig. 9a ,b) regardless of CSF Aβ 42 (Fig. 3g ,h; Extended Data Fig. 9c ), pTau status ( Fig. 3i ,j; Extended Data Fig. 9d ), or VRF status (Extended Data Fig. 9e ,f). Increased regional BBB permeability in HC, PHG, and HC subfields remained a significant predictor of cognitive impairment after statistically controlling for CSF Aβ 42 and pTau, as shown by the estimated marginal means from the ANCOVA models ( Fig. 1k ), indicating medium-to-large incremental effect sizes (η 2 partial range = 0.07-0.18), also confirmed by logistic regression analysis ( Supplementary Table 5d -h).
An increase in DCE-MRI BBB permeability in several medial temporal lobe structures that subserve episodic memory (for example, HC, PHG, and the CA1, CA3, and dentate gyrus HC subfields) was associated with worse CDR scores (CDR 0 versus 0.5) and with impairment in multiple cognitive domains (impairment in 0 versus 1+ domains) ( Fig. 1g-k; Fig. 3g-k) . Although this provides a perfect anatomical substrate for episodic memory impairment, it is less clear whether BBB pathology in the HC and medial temporal lobe can contribute to changes seen in other domains in participants with CDR 0.5 or with impairment in multiple domains, which involves areas of the brain outside the medial temporal lobe that we found were not affected by BBB breakdown in the present cohort (Extended Data Fig. 5a ,b and 9a,b). However, numerous studies have linked HC structure and function to each of the cognitive domains and subdomains investigated in the present study. For example, experimental studies in animals and observational human studies have found that attention, working memory, and executive function can become dysfunctional as a result of HC-prefrontal pathway disruption [32] [33] [34] [35] . HC functional activation has been found to underpin normal performance on semantic fluency tasks 36 ; neuroimaging-based markers of HC structure and function correlate with performance on semantic fluency and confrontation naming tasks in both normal and pathological human aging 37 . Thus, BBB breakdown within the HC and medial temporal regions may disrupt the ability of these structures and their connecting pathways to support an array of cognitive functions. Additionally, we noted increased BBB permeability in the caudate nucleus (Extended Data Fig. 5a ,b and 9a,b), a structure known to support the frontal-subcortical processes involved in attention/executive functions and verbal fluency 38, 39 . Although less salient than the HC and PHG findings, it is possible that BBB breakdown within the caudate nucleus may contribute to the observed deficits in domains beyond memory.
As with CDR analysis, there were no significant changes in HC volume, but a significant decrease in PHG volume, in participants with 1+ impaired cognitive domains compared to no impaired domains, which did not statistically differ between participants that were CSF Aβ + versus Aβ − or pTau+ versus pTau− (Fig. 4a-c) . CSF sPDGFRβ increases remained significant after controlling for HC and PHG volume (Fig. 4d) , and remained increased when stratifying by CSF Aβ 42 and pTau status (Fig. 4e,f ). HC and PHG BBB permeability increases remained significant after controlling for HC and PHG volume ( Fig. 4g) , respectively, and when stratifying by Aβ 42 and pTau status (Fig. 4h,i) . These findings exhibited mediumto-large incremental effect sizes after controlling for HC and PHG volume (η 2 partial range = 0.19-0.25) and were corroborated by logistic regression models ( Supplementary Table 6a -c).
Finally, we asked the following question. Did CSF sPDGFRβ and DCE-MRI BBB increases correlate with age? Neither CSF sPDGFRβ (Extended Data Fig. 10a ,b) nor regional BBB permeability HC and PHG values (Extended Data Fig. 10c-f ) were correlated with age in either the CDR 0 or CDR 0.5 groups. Since all CDR and domain impairment group differences in CSF sPDGFRβ and in HC and PHG BBB permeability values were significant after correcting for age ( Fig. 1; Fig. 3 ), these data indicate that CSF sPDGFRβ and HC and PHG BBB measures reflect cognitive impairment independent of normal aging; therefore, they may be good biomarkers of early cognitive dysfunction.
In summary, we show that older adults with early cognitive dysfunction develop brain capillary damage associated with mural cell pericyte injury and BBB breakdown in the HC irrespective of Aβ and/or tau changes, suggesting that BBB breakdown is an independent, early biomarker of cognitive impairment unrelated to Aβ and tau. The independence of the BBB breakdown pathway from the Aβ /tau pathway in predicting cognitive impairment is further supported by logistic regression models indicating that BBB breakdown is not mediating the relationship between AD biomarkers and cognitive impairment ( Supplementary Tables 7-10 ). Biomarker-based diagnostic approaches, including the recent research recommendations for AD 17 , mention vascular biomarkers, but suggest that CSF Aβ 42 and pTau, and amyloid PET and tau PET, are the key biomarkers defining AD pathology, although they may not be causal to the disease process 5, 17, 40 . Our present findings support that neurovascular dysfunction may represent a previously underappreciated factor contributing to cognitive and functional decline, independent of the classic pathophysiological hallmarks of AD. Moreover, our findings point to the brain vasculature as an important new biomarker of cognitive dysfunction in both individuals without and with Aβ or pTau positivity, the latter indicating individuals in the Alzheimer's continuum 17 .
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-018-0297-y.
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Methods Study participants. Participants were recruited from two sites, including the University of Southern California (USC), Los Angeles, and Washington University, St. Louis. At the USC site, participants were recruited through the USC Alzheimer's Disease Research Center (ADRC): combined USC and Huntington Medical Research Institutes in Pasadena. At the Washington University site, participants were recruited through the Washington University Knight ADRC. The study and procedures were approved by the Institutional Review Board (IRB) of the USC ADRC and Washington University Knight ADRC indicating compliance with all ethical regulations; informed consent was obtained from all participants before study enrollment. Participants from both sites were included in CSF biomarker studies. All participants underwent neurological and neuropsychological evaluations performed using the Uniform Data Set (UDS), and additional neuropsychological tests, as described in the following sections. Participants from the USC ADRC were included in DCE-MRI studies for assessment of BBB permeability if they had no contraindications for contrast injection or MRI.
We included 161 participants for the CSF biomarker studies (74 from USC/ Huntington Medical Research Institutes and 87 from Washington University). A group of 35 participants from the Washington University Knight ADRC underwent PiB-PET imaging for amyloid-β . A group of 73 participants recruited from the USC ADRC underwent DCE-MRI. All biomarker assays and quantitative MRI scans were conducted by investigators blinded to the clinical status of the participant.
Inclusion and exclusion criteria. Included participants (≥ 45 years of age) with neuropsychologically confirmed no cognitive dysfunction and/or early cognitive dysfunction had no current or prior history of any neurological or psychiatric conditions that might better account for any observed cognitive impairment, including organ failure, brain tumors, epilepsy, hydrocephalus, schizophrenia, and major depression. Participants were stratified based on CSF analysis as either Aβ 42 -positive (Aβ 42 + , < 190 pg ml −1 ) or Aβ 42 -negative (Aβ − , > 190 pg ml −1 ), or pTau 181positive (pTau+ , > 78 pg ml −1 ) or pTau 181 -negative (pTau− , < 78 pg ml −1 ), using the accepted cutoff values [19] [20] [21] . Participants were excluded if they were diagnosed with vascular cognitive impairment or vascular dementia. These clinical diagnoses were conducted by neurologists based on the criteria of whether the patient (1) had a known vascular brain injury and (2) the clinician judged that the vascular brain injury played a role in their cognitive impairment, and/or pattern and course of symptoms. In addition to clinical diagnosis, presence of vascular lesions was confirmed by moderate-to-severe white matter changes and lacunar infarcts by fluid-attenuated inversion recovery MRI and/or subcortical microbleeds by T2*-weighted MRI 13 . Participants were also excluded if they were diagnosed with Parkinson's disease, Lewy body dementia, or frontotemporal dementia. History of a single stroke or transient ischemic attack was not an exclusion unless it was related to symptomatic onset of cognitive impairment. Participants also did not have current contraindications to MRI and were not currently using medications that might better account for any observed cognitive impairment. CDR. CDR assessments followed the standardized UDS procedures. Participants underwent clinical interview, including health history, and a physical examination. Knowledgeable informants were also interviewed. Given the lack of scientific consensus regarding the categorization of older adults along the aging to MCI to AD dementia spectrum and the time course and sequence of biomarker abnormalities, we did not use clinical diagnosis in our biomarker comparisons but rather stratified participants along objective neuropsychological metrics of cognitive impairment and biological metrics of AD biomarker status using established cutoffs 19, 20 . Each participant's CDR score was obtained through standardized interview and assessment with the participant and a knowledgeable informant.
Neuropsychological evaluation and domain impairment.
Neuropsychological performance was used to identify domain impairment. All participants underwent neuropsychological testing using the UDS battery (version 2.0 or 3.0) plus supplemental neuropsychological tests at each site. Test impairment for the UDS tests was determined using age-, sex-, and education-corrected scores from the National Alzheimer's Coordinating Center (www.alz.washington.edu). Normalized scores from a total of ten neuropsychological tests were used in determining domain impairment, including three tests per cognitive domain (memory, attention/ executive function, and language) and one test of global cognition. Domain impairment was determined using previously described neuropsychological criteria 21 , and was defined as a score > 1 s.d. below norm-referenced values on two or more tests within a domain 41 . Multiple domain impairment (2+ ) was assigned when more than one domain fitted the impairment criteria, or three or more tests were impaired across domains 21, 41 . Prior studies have established improved sensitivity and specificity of these criteria relative to those employing a single test score, as well as adaptability of this diagnostic approach to various neuropsychological batteries 21, 41, 42 . Cognition was presumed normal unless multiple impaired tests were identified as specified by the criteria. Individuals with low Mini Mental State Examination or Montreal Cognitive Assessment scores (< 25) who had multiple missing neuropsychological test scores due to difficulty completing testing were considered to have domain impairment. Test battery specifics for each UDS version and recruitment site are listed in the following sections. 
Memory. The Logical Memory Story A (Immediate and Delayed recall) free recall tests (modified from the original Wechsler Memory Scales-Third Edition)
were used for UDS version 2.0 and the Craft Stories immediate and delayed free recall was used for UDS version 3.0. For supplemental tests, the USC participants underwent the California Verbal Learning Test-Second Edition and the Selective Reminding Test sum of free recall trials. Norm-referenced scores for these supplemental test scores were derived from a nationally representative sample published with the test manual (California Verbal Learning Test-Second Edition) 43 and in studies of normally aging adults (Selective Reminding Test).
Attention and executive function. The Trails A, Trails B, Wechsler Adult Intelligence Scale-Revised, and Digit Span Backwards tests were used for UDS version 2.0 and the Trails A, Trails B, and Digit Span Backwards test for UDS version 3.0.
Language. The Animal Fluency, Vegetable Fluency, and Boston Naming Tests were used for UDS version 2.0 and the Animal Fluency, Vegetable Fluency, and Multilingual Naming Test for UDS version 3.0.
VRFs. The participants' VRF burden was evaluated through physical examination, clinical blood tests, and interviews with the participant and informant; it included a history of cardiovascular disease (heart failure, angina, stent placement, coronary artery bypass graft, intermittent claudication), hypertension, hyperlipidemia, type 2 diabetes, atrial fibrillation, and transient ischemic attack or minor stroke. The total VRF burden was defined by the sum of these risk factors. We have previously shown that older adults with AD who exhibit two or more VRFs are more likely to exhibit occult cerebrovascular disease at autopsy, whereas a single VRF is common and not necessarily associated with increased cerebrovascular disease in this population 44, 45 . Thus, an elevated VRF burden was defined as an individual having two or more VRFs.
Lumbar puncture and venipuncture. Participants underwent lumbar puncture in the morning after an overnight fast. The CSF was collected in polypropylene tubes, processed (centrifuged at 2,000g, 10 min, 4 °C), aliquoted into polypropylene tubes, and stored at − 80 °C until assay. Participants underwent venipuncture in the morning after an overnight fast. Blood was collected into EDTA tubes and processed (centrifuged at 2,000g, 10 min, 4 °C). Plasma and buffy coat were aliquoted in polypropylene tubes and stored at − 80 °C; buffy coat was used for DNA extraction and APOE genotyping. Molecular biomarkers in the CSF assays. Quantitative western blot analysis of sPDGFRβ . Quantitative western blot analysis was used to detect sPDGFRβ in human CSF (ng ml −1 ), as we previously reported 8 . Standard curves were generated using recombinant human PDGFRβ Fc Chimera Protein (R&D Systems).
Astrocyte marker. CSF levels of the astrocytic cytokine S100B were determined using an enzyme-linked immunosorbent assay (ELISA; EMD Millipore).
Inflammatory markers.
A Meso Scale Discovery (MSD) multiplex assay was used to determine CSF levels of interleukin-2 (IL-2), IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-1β , tumor necrosis factor-α (TNFα ), and interferon γ (MSD).
Aβ peptide. An MSD multiplex assay was used to determine the CSF levels of Aβ 38 , Aβ 40 , and Aβ 42 . The CSF Aβ 42 cutoff level of 190 pg ml −1 was applied as previously reported for the MSD Aβ peptide assay 19 .
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Aβ oligomers. CSF Aβ oligomers were measured using ELISA (IBL; protocol modified from IBL and Hölttä et al. 46 ). The Aβ 1-16 peptide dimer was used as the standard protein prepared at 0, 1, 2.5, 5, 7.5, 10, 15, 20 pM, and 100 µ l of prepared standards and neat CSF were added to each well on an uncoated 96-well plate along with 20 µ l per well of horseradish peroxidase (HRP)-conjugated antihuman Aβ (N) (82E1) mouse immunoglobulin G (IgG) monoclonal antibody; the plates were incubated overnight at 4 °C on an orbital plate shaker at 600 r.p.m, and 100 µ l per well was transferred to a 96-well plate precoated with antihuman Aβ (N) (82E1) mouse IgG monoclonal antibody and incubated for 1 h at 4 °C with shaking. Plates were washed with Tris-buffered saline with 0.1% Tween 20 (TBST). ELAST ELISA amplification was performed (PerkinElmer). Briefly, 100 µ l per well of biotinyl tyramide (1:100 dilution) was incubated for 15 min at room temperature with shaking. Plates were washed and 100 µ l per well of HRP-conjugated streptavidin (1:500 dilution) was incubated for 30 min at room temperature with shaking. Plates were washed and 100 µ l per well of tetramethylbenzidine substrate (Kirkegaard & Perry Laboratories) was incubated in the dark for 60 min, then 100 µ l per well of 2 N HCl was added, and the plates were read at 450 nm.
Tau. An MSD assay was used to determine the CSF levels of total tau. Phosphorylated tau (pT181) was determined by ELISA (INNOTEST PHOSPHO-TAU (181P) ). The CSF pTau 181 cutoff level of 78 pg ml −1 was applied as previously reported 20 .
Tau oligomers. CSF tau oligomers were measured by direct ELISA using tau oligomer-specific antibody (T22) 47 . Briefly, 12 µ l CSF was diluted in a total volume of 50 µ l 0.05 M carbonate-bicarbonate buffer, added to a 96-well Nunc MaxiSorp plate (Nunc) and incubated overnight at 4 °C on an orbital plate shaker at 600 r.p.m. Plates were washed (TBST) and blocked with 300 µ l of 10% non-fat dry milk (Bio-Rad) for 2 h at room temperature with shaking. Plates were washed and incubated with 100 µ l per well of T22 antibody (1:250 diluted in 5% non-fat milk) and incubated for 1 h at room temperature with shaking. Plates were washed and incubated with HRP-conjugated anti-rabbit IgG antibody (1:3,000 diluted in 5% non-fat dry milk) and incubated for 1 h at room temperature with shaking. Plates were washed and incubated in the dark with 100 µ l per well tetramethylbenzidine substrate for 14 min; then, 100 µ l per well 2 N HCl was added, and the plates were read at 450 nm.
Neuronal marker. CSF levels of neuron-specific enolase (NSE) were determined using ELISA (Immunology Consultants Laboratory).
In vitro analysis of sPDGFRβ shedding. Primary human brain mural cell isolation and culture. Primary human brain vascular SMCs were isolated from leptomeningeal arteries (> 100 µ m diameter) as described and characterized previously 18 . SMCs were > 98% positive for α -smooth muscle actin, myosin heavy chain, calponin, and SM22 and negative for von Willebrand factor (endothelial cells), glial fibrillary acidic protein (astrocytes) and CD11b (microglia). Cells were cultured in SMC medium (ScienCell) in 5% CO 2 at 37 °C. Early passage (P5, P6) cultures were used in the present study.
Primary human brain microvascular pericytes were isolated from cortical brain tissue after removal of leptomeninges as described previously 18, 48 . Pericytes were derived from intraparenchymal microvessels that were completely free from leptomeningeal vessel contamination. Purified microvessels were largely brain capillaries (> 97%) with a diameter < 6 µ m. Cells were cultured in human pericyte medium (ScienCell) in 5% CO 2 at 37 °C and were then characterized. Pericytes were positive for the pericyte markers PDGFRβ , neural/glial antigen 2, and CD13 and negative for von Willebrand factor (endothelial cells), glial fibrillary acidic protein (astrocytes) and CD11b (microglia). Early passage (P5, P6) cultures were used in the present study.
Treatment conditions. Primary human brain SMCs and pericytes were plated in equal cell number for all conditions. For ADAM10 knockdown, Accell Human ADAM10 (102) siRNA (Dharmacon) at a final concentration of 1 µ M in Accell siRNA Delivery Media (Dharmacon) was added into 90% confluent cultured pericytes in 12-well tissue culture plates; after 96 h, as recommended by the manufacturer, cells underwent treatment conditions. Specifically, cells were subjected to treatment with ionomycin (2.5 µ M) and/or marimastat (4 µ M) prepared in reduced serum Gibco Opti-MEM (Thermo Fisher Scientific) or media only (control condition) for 40 min at 37 °C, as described previously 27 . After 40 min, the media and cell lysates were collected for additional analysis described in the next section.
Immunoprecipitation of sPDGFRβ . Immunoprecipitation was performed on the pericyte and SMC media as described by the manufacturer with optimizations (all wash steps performed as described). For antibody-bead coupling, 50 µ l Invitrogen Dynabeads Protein G (Thermo Fisher Scientific) and 2 µ g of PDGFRβ antibody (goat antihuman; R&D Systems) were incubated with rotation for 10 min at room temperature. Conditioned media and equal volume lysis buffer were added to the Dynabeads-coupled PDGFRβ antibody and incubated with rotation for 30 min at room temperature. Target antigen was eluted in denaturing conditions and a quantitative western blot was performed as described in the next section.
Western blot analysis. A quantitative western blot on immunoprecipitated media was performed using carrier-free human recombinant PDGFRβ as a protein standard (R&D Systems). Gel transfer was performed using iBlot 2 (Thermo Fisher Scientific) at 20 V for 9 min. The nitrocellulose membrane was incubated with SuperBlock (TBS) Blocking Buffer (Thermo Fisher Scientific) for 1 h at room temperature and primary antibody (R&D Systems, 1 µ g ml −1 ) prepared in SuperBlock was incubated overnight at room temperature with shaking. Secondary anti-goat antibody (1:5,000) prepared in 5% non-fat dry milk was incubated for 1 h at room temperature with shaking. SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific) and film was used to develop the membrane; sample protein concentration (ng ml −1 ) was calculated.
Western blot analysis of primary human brain pericyte cell lysates was performed with primary antibodies ADAM10 (Abcam) and glyceraldehyde 3-phosphate dehydrogenase (Cell Signaling Technology).
MRI. The MRI dataset was obtained from the USC Keck Medical Center. The study was approved by the USC IRB. All participants underwent a blood draw to ensure appropriate kidney function for contrast agent administration before imaging. The imaging protocol performed was developed to detect subtle BBB changes in patients with cognitive impairment and is detailed in Montagne et al. 8 . Briefly, all images were obtained on a GE 3 T HDXT MR scanner with a standard eight-channel array head coil. Anatomical coronal spin echo T2-weighted scans were first obtained through the left and right HC (TR/TE 1550/97.15 ms, number of excitations = 1, slice thickness 5 mm with no gap, field of view = 188 × 180 mm 2 , matrix size = 384 × 384). Baseline coronal T1-weighted maps were then acquired using a T1-weighted three-dimensional (3D) spoiled gradient echo pulse sequence and variable flip angle method using flip angles of 2°, 5°, and 10°. Coronal DCE-MRI covering the left and right HC and temporal lobes were acquired using a T1weighted 3D spoiled gradient echo pulse sequence (fractional anisotropy = 15°, TR/ TE 8.29/3.09 ms, number of excitations = 1, slice thickness 5 mm with no gap, field of view 188 × 180 mm 2 , matrix size 160 × 160, voxel size 0.625 × 0.625 × 5 mm 3 ). This sequence was repeated for a total of 16 min with an approximate time resolution of 15.4 s. The gadolinium-based contrast agents gadobenate dimeglumine (MultiHance; Bracco) or meglumine gadoterate (Dotarem; Guerbet) (0.05 mmol kg −1 ) were administered intravenously into the antecubital vein using a power injector, at a rate of 3 ml s −1 followed by a 25 ml saline flush, 30 s into the DCE scan.
Quantification of subtle BBB permeability.
Post-processing analysis was performed using ROCKETSHIP 49 running with Matlab. The arterial input function (AIF), which was extracted from a region of interest (ROI) positioned at the internal carotid artery, was fitted with a bi-exponential function before fitting with the Patlak model 50 . The Patlak linearized regression mathematical analysis was used to generate the BBB permeability K trans maps 8, 49, 50 with high spatial and temporal resolutions allowing not only simultaneous measurements of the regional BBB permeability in different white and gray matter regions, but also accurate calculations of the K trans values in anatomical regions as small as the subdivisions of the HC. We determined in each individual AIF from the internal carotid artery. In a few cases when the common carotid artery was not clearly visible, a nearby large vessel was used. Individual AIF measurements are important particularly if the studied population diverges by age, since changes in blood volume and flow may affect AIF and the K trans measurements.
The present analysis requires that the tracer's diffusion across the BBB remains unidirectional during the acquisition time. The total tracer concentration in the tissue, C tissue (t), can be described as a function of the blood concentration, C AIF (t), the intravascular blood volume, v p , and a blood-to-brain transfer constant, K trans , that represents the flow from the intravascular to the extravascular extracellular space using the following equation:
A statistically significant intersubject variability in the measurement of v p was not observed.
ROI-averaged analysis of DCE-MRI output maps was performed by an experienced neuroradiologist who manually drew ROIs for each participant based on their own anatomy since a substantial variability between individuals is seen at a macroscopic level (for example, enlarged ventricles, cortical atrophy, hippocampal shrinkage). Thus, regional BBB K trans permeability was measured in 13 different gray matter ROIs including the left and right HC and their subfields (that is, CA1, CA3, and the dentate gyrus), parahippocampal gyrus (PHG), caudate nucleus, superior frontal cortical gyri, inferior temporal cortical gyri, thalamus, and striatum and white matter ROIs including subcortical white matter fibers, corpus callosum, and internal capsule. Quantification of regional brain volumes. HC and PHG morphometry were performed using the FreeSurfer (version 5.3.0) software package 51 , which is documented and freely available online (http://surfer.nmr.mgh.harvard.edu/).
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In brief, the HC and PHG were segmented using the included FreeSurfer Desikan-Killiany and subcortical atlases 52, 53 . Then, regional volumes (mm 3 ) were derived accordingly. The technical details of this procedure are described in previous publications 54, 55 . Data processing was performed using the Laboratory of Neuro Imaging pipeline system (http://pipeline.loni.usc.edu) 56, 57 .
PET. PiB-PET imaging was conducted at the Washington University Knight ADRC using procedures and analysis described previously 58, 59 .
Statistical analyses. All continuous variables were screened for outliers (± 3 s.d. from the mean) and evaluated for departures from normality through quantitative examination of skewness and kurtosis, as well as visual inspection of frequency distributions. Where departures of normality were identified, log 10 -transformations were applied, and distribution normalization was confirmed before parametric analyses. Participant demographics and clinical characteristics were initially compared across both CDR and domain impairment stratifications using chi-squared tests and one-way analyses of variance (ANOVAs), with post-hoc Tukey tests.
All CSF biomarkers were compared in parallel analyses applied across the entire sample stratified by the global CDR score and the number of impaired cognitive domains using ANCOVA, with post-hoc Bonferroni-corrected comparisons. For CDR analyses, model covariates included age, sex, education, and APOE-ε4 carrier status. For domain impairment analyses, age, sex, and educationcorrected values were used to identify impairment groups and APOE-ε4 carrier status was used as a covariate. Site-specific analyses and interaction effect analyses did not include APOE-ε4 carrier status as a covariate to conserve statistical power. For the analysis of interactions by Aβ 42 , pTau, and VRF burden, statistical interactions and main effects were examined in similar ANCOVA models.
The same approach described was used in all analyses of other CSF glial, inflammatory, and neuronal markers, and for the DCE-MRI data. With regard to missing data, all participants had complete data for primary outcomes (CSF sPDGFRβ and DCE-MRI); the extent of missing data was capped at < 10% for all other CSF biomarkers and clinical measures (that is, > 90% of participants had complete data).
Given the large number of analyses, false discovery rate (FDR) correction was applied to all ANCOVA omnibus P values using the Benjamini-Hochberg method 60 .
Where significant CSF sPDGFRβ and BBB K trans findings were identified (CDR 0.5 versus 0 and domain impairment 1+ versus 0), separate post-hoc analyses of CSF sPDGFRβ and BBB K trans differences controlling for CSF Aβ 42 and pTau, PiB-PET amyloid deposition, pTau oligomers, and HC and PHG volumes also utilized ANCOVA models. In addition, separate hierarchical logistic regression analyses evaluated whether CSF sPDGFRβ and BBB K trans predicted cognitive impairment (CDR 0.5 versus 0 and domain impairment 1+ versus 0) after controlling for CSF Aβ 42 and pTau, PiB-PET amyloid deposition, pTau oligomers, and HC and PHG volumes. For both ANCOVA and logistic regression analyses, covariates were entered into the model in the first block; in the second block, either CSF sPDGFRβ or specific regional BBB K trans values were entered. Additional demographics and APOE4 carrier status were included in the overall models correcting for CSF Aβ 42 and pTau, and models correcting for HC and PHG volumes. 
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Extended Data Fig. 7 | BBB breakdown is independent of amyloid and tau oligomers. a, CSF sPDGFRβ is increased with impaired cognitive domains, independent of amyloid positivity by PiB-PET; supports Fig. 3d-f . b-c, No differences were observed in CSF Aβ (b) and tau (c) oligomer levels in individuals with 0 or 1+ impaired cognitive domains. d-e, Increases in CSF sPDGFRβ (d) and regional BBB K trans in the HC and PHG (e) of individuals with 1+ versus 0 cognitive domain impairment remain significant after statistically controlling for the impact of CSF tau oligomers; supports Fig. 3d-f. a-c 
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Extended Data Fig. 9 | Regional BBB breakdown K trans increases with cognitive domain impairment, independent of CSF Aβ, tau, and VRFs. a-b, An increase in K trans values in the HC, PHG, and the CA1, CA3, and dentate gyrus HC subfields with increasing cognitive impairment measured by the number of impaired cognitive domains (a), but not in other brain regions, including the superior frontal cortical gyrus and the inferior temporal cortical gyrus, white matter regions including the subcortical white matter fibers, corpus callosum, and internal capsule, and deep gray matter regions including thalamus, caudate nucleus, and striatum (b). c-d, Additional brain regions showed no significant difference in K trans BBB permeability in individuals with 0 and 1+ impaired cognitive domains, regardless of CSF Aβ 42 (c) and pTau (d) status. e-f, K trans BBB permeability is increased with increasing cognitive domain impairment in the HC, PHG, and HC subfields (that is, CA1, CA3, and dentate gyrus), independent of VRF burden (e), but not in other brain regions (f). VRFs 0-1: no or 1 VRF; VRFs 2+ : 2 or more VRFs. See Supplementary Table 2 A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Our GUI code (https://github.com/petmri/ROCKETSHIP) running with Matlab R2013a was used for DCE-MRI analyses. We also used FreeSurfer (v5.3.0) software package for regional brain volume analyses.
Data analysis
Statistical analyses were conducted with a commercial statistical software package --SPSS (IBM). No custom software was used.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability A full data availability statement is included in the manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request.
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Validation
Recombinant human PDGFRbeta protein (R&D Systems Catalog #385-PR/CF, Lot #AMO0714072) was used as a positive control in validating the antibodies. Consistently, the manufacture's website specifies this antibody exhibits approximately 35% crossreactivity with recombinant human PDGFRbeta.
Human research participants
Policy information about studies involving human research participants
Population characteristics
We studied 161 participants with clinical dementia ratings of 0 (n=82), 0.5 (n=63), or 1 (n=16), who exhibited no cognitive domain impairment (n=83), one impaired domain (n=39) or two or more impaired domains (n=39). Relevant covariates (means +/-standard deviations) included age (72.3 +/-9.6 years), sex (51.6% male), education (15.5 +/-9.6 years) and APOE4 carrier status (44.5%). 
Method
Area of acquisition
Scan was coronal with slices covering hippocampi, temporal lobes and other in plane regions. These regions were chosen due to their importance in aging, cognitive decline, Alzheimer's disease, and prior studies of blood-brain barrier dysfunction in older adults.
Diffusion MRI Used Not used
Preprocessing Preprocessing software From Online Methods: -Blood-brain barrier permeability: Post-processing analysis was performed using Rocketship71 running with Matlab. The arterial input function (AIF), which was extracted from a region-of-interest (ROI) positioned at the internal carotid artery, was fitted with a bi-exponential function prior to fitting with Patlak model72. The Patlak linearized regression mathematical analysis was used to generate the BBB permeability Ktrans maps8,71,72 with high spatial and temporal resolutions allowing not only simultaneous measurements of the regional BBB permeability in different white (WM) and gray matter (GM) regions, but also accurate calculations of the Ktrans values in anatomical regions as small as the subdivisions of the hippocampus. We determined in each individual AIF from the internal carotid artery.
-Volumetric analysis: Hippocampus (HC) and parahippocampus (PHC) morphometry were performed using the FreeSurfer (v5.3.0) software package73, which is documented and freely available online (http:// surfer.nmr.mgh.harvard.edu/). In brief, HC and PHC gyri were segmented using the included FreeSurfer Desikan-Killiany and subcortical atlases74,75. Then, regional volumes (mm3) were derived accordingly. The technical details of this procedure are described in previous publications76-79. Data processing was performed using the Laboratory of Neuro Imaging (LONI) pipeline system (http://pipeline.loni.usc.edu)80-84.
Normalization N/A
